FDA Approved: ADVAIR HFA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for Advair HFA, the combination inhaled therapy of fluticasone propionate and salmeterol xinafoate, submitted by Gla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Advair HFA (fluticasone propionate/salmeterol)

Snippet

SUPPL AP for ADVAIR HFA (FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE)